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Abstract
Background: Only a minority of patients with advanced non-small cell lung cancer (NSCLC)
benefit from chemotherapy. Serum peptide profiling of NSCLC patients was performed to
investigate patterns associated with treatment outcome.
Using magnetic bead-assisted serum peptide capture coupled to matrix-assisted laser desorption/
ionization time-of-flight mass spectrometry (MALDI-TOF-MS), serum peptide mass profiles of 27
NSCLC patients treated with cisplatin-gemcitabine chemotherapy and bortezomib were obtained.
Support vector machine-based algorithms to predict clinical outcome were established based on
differential pre-treatment peptide profiles and dynamic changes in peptide abundance during
treatment.
Results: A 6-peptide ion signature distinguished with 82% accuracy, sensitivity and specificity
patients with a relatively short vs. long progression-free survival (PFS) upon treatment. Prediction
of long PFS was associated with longer overall survival. Inclusion of 7 peptide ions showing
differential changes in abundance during treatment led to a 13-peptide ion signature with 86%
accuracy at 100% sensitivity and 73% specificity. A 5-peptide ion signature could separate patients
with a partial response vs. non-responders with 89% accuracy at 100% sensitivity and 83%
specificity. Differential peptide profiles were also found when comparing the NSCLC serum profiles
to those from cancer-free control subjects.
Conclusion: This study shows that serum peptidome profiling using MALDI-TOF-MS coupled to
pattern diagnostics may aid in prediction of treatment outcome of advanced NSCLC patients
treated with chemotherapy.
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Background
Lung cancer is the most common cause of cancer-related
death with an overall 5-year survival rate of 16% [1]. Non-
small cell lung cancer (NSCLC) accounts for approxi-
mately 85% of lung carcinomas and is frequently diag-
nosed in an advanced stage [2]. First-line treatment of
advanced NSCLC typically consists of platinum-based
chemotherapy [3,4]. Only a minority of patients respond
to this treatment, at the cost of substantial toxicity for all
treated patients [5]. There is an urgent need for methods
enabling outcome prediction in order to select patients
likely to benefit from treatment.
The serum peptidome, that comprises peptides and pro-
teins with a molecular weight of less than 10 kDa, repre-
sents a dynamic reflection of tissue function in health and
disease [6]. Mass spectrometry (MS) is increasingly used
to profile the serum peptidome [7-9]. Peaks in the serum
peptide spectra correspond to peptide ions, with the
amplitude of the peaks indicative of relative abundance
[10]. Magnetic bead-assisted serum peptide capture cou-
pled to matrix assisted laser desorption/ionization time-
of-flight MS (MALDI-TOF-MS) is a serum peptide profil-
ing strategy gaining in popularity compared to surface-
enhanced laser desorption/ionization (SELDI)-based
platforms due to superior resolution of MALDI instru-
ments, the possibility to obtain structural (MS/MS) infor-
mation of signature peptides and superior binding
capacity of the magnetic beads compared to a flat SELDI-
chip surface [11].
Here we report on a MALDI-TOF-MS dataset of serum
samples from advanced NSCLC patients, who were
treated with first-line chemotherapy, consisting of cispla-
tin and gemcitabine, as well as bortezomib, in a previ-
ously reported prospective clinical trial [12]. The efficacy
of cisplatin-gemcitabine alone is limited, a partial tumor
response being achieved in about one third of NSCLC
patients and with a median progression free survival of
four to five months [13]. Preclinical as well as initial clin-
ical studies suggested combining cisplatin-gemcitabine
with proteasome inhibitor bortezomib might enhance
efficacy [14-17].
We hypothesized that specific serum peptidome patterns
could predict clinical outcome of patients who underwent
chemotherapy-based treatment. For this purpose, data
analyses of serum peptide profiles were conducted. Our
primary aim was to establish serum peptide signatures
that could predict positive or negative clinical outcome
upon treatment. Clinical endpoints used to establish
these signatures were response to treatment according to
the Response Evaluation Criteria in Solid Tumors
(RECIST) criteria, as well as progression-free survival
duration of treated patients. Furthermore, in a secondary
analysis, we compared the serum peptide profiles of
treated patients with those obtained from cancer-free con-
trol subjects in an initial attempt to establish cancer-spe-
cific serum peptide patterns.
Results
Pre-treatment serum peptide patterns of NSCLC patients
First, pre-treatment serum spectra of 27 NSCLC patients
were determined. See Table 1 for patient characteristics.
Six hundred eighty-two peaks could be distinguished. The
intra-run and inter-run coefficients of variance were 16%
and 18%, respectively.
Time-course analysis
We first looked for peptides that exhibited significant
changes in intensity level in three time points: (1) pre-
treatment (preTx), (2) after two cycles of treatment (Post-
2), and (3) at the end of treatment (EOT). Forty-four
peaks were determined as significant (Table 2). The spec-
tra overlay of the top 8 peaks is illustrated in Figure 1.
Note that for example the peak at m/z 2567.3659 has a
higher intensity at end of treatment (green) compared to
pre-treatment (red) and the peak at m/z 1561.7288 has a
lower intensity at end of treatment compared to pre-treat-
ment.
Table 1: Patient characteristics
NSCLC patients
(n = 27)
Age, years
Median 53
Range 35-67
Sex, n (%)
Male 15 (55.6)
Female 12 (44.4)
Stage, n (%)
IIIB 5 (18.5)
IV 22 (81.5)
Histology, n (%)
Squamous cell carcinoma 6 (22.2)
Adenocarcinoma 12 (44.4)
Adenosquamous cell carcinoma 2 (7.4)
Undifferentiated non-small cell carcinoma 7 (25.9)
Karnofski performance status, n (%)
70 4 (14.8)
80 10 (37.0)
90 8 (29.6)
100 5 (18.5)
Smoking history, n (%)
No 1 (3.7)
Current or former 26 (96.3)
RECIST, n (%)
Partial response 9 (33.3)
Stable disease 15 (55.6)
Progressive disease 3 (11.1)
Survival, days
Median progression-free survival 152
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Analysis of the clinical outcome: progression-free survival
The patients were divided into two subsets according to
PFS duration. Of the 27 NSCLC patients, 11 patients with
the shortest PFS were nominated as "short PFS" group
(PFS ≤ 127 days), 11 patients with the longest PFS were
nominated as "long PFS" group (PFS ≥ 178 days). Four
patients with PFS duration around the median PFS (152
days) were excluded from the analysis. A fifth patient was
excluded who had a partial response but died 36 days after
start of treatment due to a cause not likely due to tumor
progression [12].
Six differentially expressed peptides between the two
groups were detected (see Figure 2A and Table 3). Median
intensity of all six peptides was higher in the "short PFS"
group compared to the "long PFS" group. This 6-peptide
signature was used to retrospectively divide the total study
population (n = 27) into a predicted "short PFS" group
and a predicted "long PFS" group. Median PFS was signif-
icantly shorter at 120 days (95% CI 54-186 days) in
patients predicted to have a short PFS vs. 191 days (95%
CI 154-228 days) in patients predicted to have a long PFS
(p-value: 0.036). Median overall survival (OS) of patients
predicted to have short PFS vs. long PFS was 144 days
Comparison serum profiles time course Figure 1
Comparison serum profiles time course. Top 8 differential peaks that exhibit changes over the three time points: pre-
treatment (PreTx) (red), after two cycles of treatment (Post-2) (blue), and at end of treatment (EOT) (green). Eight peaks ran-
domly selected out of the remaining 638 peaks. Each overlay contains spectra with normalized intensities.Proteome Science 2009, 7:34 http://www.proteomesci.com/content/7/1/34
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(95% CI 75-213 days) vs. 436 days (95% CI 292-580
days) (p-value: 0.036) (Figure 2B). For the OS analyses,
two patients were censored at last known date to be alive.
When considering also Post-2 and EOT samples, we
found seven differential peptides distinguishing the clini-
cal groups (see Figure 2C and Table 4). These peptides do
not overlap with peptides from the pre-treatment signa-
ture. Using the combined 13-peptide signature to classify
the total study population, median PFS was significantly
shorter at 120 days (95% CI 70-170 days) in patients pre-
dicted to have a short PFS vs. 199 days (95% CI 181-217
days) in patients predicted to have a long PFS (p-value: <
0.001). Median overall survival of patients predicted to
have short vs. long PFS was 144 days (95% CI 96-192
Table 2: Comparison serum profiles time-course
m/z p-value peptide ID
904.4726 0.00054514 BK
1129.4849 0.0013845 FPB
1183.5995 0.0094174
1201.5663 0.0045301
1263.5958 0.0024011 FPA
1288.6006 0.0013845
1347.5297 0.047967
1350.6275 0.0013845 FPA
1389.6433 0.0013845
1402.671 0.0089624
1418.539 0.026155
1432.644 0.039554
1440.5407 0.011867
1445.5828 0.0032159
1447.6855 0.005355
1450.4893 0.024048
1456.5093 0.039554
1458.4946 0.020271
1460.6257 0.0022586
1477.6539 0.010181
1479.6646 0.005355
1487.6226 0.0017206
1491.6634 0.0074232
1501.748 0.011
1503.5994 0.0087051
1507.6643 0.0024697
1536.6906 0.0087051 FPA
1552.669 0.003822 Glu-FBP
1561.7288 0.00048292
1569.6823 0.0014303
1573.7005 0.0022586
1616.6366 0.013817 P-FPA
1630.6679 0.0022586
1670.5947 0.011876
1690.9254 0.03325 C3f
1777.966 0.0087051 C3f
1865.0022 0.011 C3f
2494.1536 0.030814
2567.3659 0.00032806 seAlb
2602.3048 0.019183 CF XIIIA
2743.4663 0.005355
2747.4349 0.0014303
2789.0914 0.037043
3156.6207 0.020803 ITIH4
In NSCLC patients, 44 peaks were significantly differential over the 
three time points: pre-treatment, after two cycles of treatment and 
end of treatment. Ordered by m/z value. Abbreviations: BK: 
bradykinin; FBP: fibrinopeptide B; FPA: fibrinopeptide A; Glu-FPB: 
Glu-1-fibrinopeptide B; P-FPA: phospho-fibrinopeptide A; C3f: 
complement C3 f; seAlb: serum albumen; CFXIIIA: coagulation factor 
XIIIA; ITIH4: inter-alpha-trypsin inhibitor heavy chain H4.
Table 2: Comparison serum profiles time-course (Continued)Proteome Science 2009, 7:34 http://www.proteomesci.com/content/7/1/34
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days) vs. 478 days (95% CI 203-753 days) (p-value:
0.002) (Figure 2D).
Finally, we carried out classification analysis using sup-
port vector machine. Using all 682 peptides, the LOOCV
accuracy was very poor, at about 50%. When the six differ-
ential pre-treatment peptides were used, the LOOCV accu-
racy was 82% with both 82% sensitivity and 82%
specificity. Selecting six different peptides randomly
resulted in an average accuracy of 68% (10 runs). The
LOOCV prediction accuracy improved when we used also
the seven peptides that changed differently in intensity
level over the three time points. Here, using the 13 pep-
tides we could separate the two groups with a LOOCV
accuracy of 86% at 100% sensitivity and 73% specificity
(the average accuracy over 10 runs with random selection
of 13 peptides was 71%).
Analysis of the clinical outcome: tumour response
To identify a signature associated with tumour response,
we divided the patients into three groups according to
tumour response following treatment: (1) partial
response (PR), (2) stable disease (SD), (3) progressive dis-
ease (PD), as defined by RECIST [18]. Because there were
only three patients with progressive disease, we created
two groups: PR and SD/PD combined ("no PR"). The first
group had 9 patients, and the second group consisted of
18 patients.
Comparing pre-treatment samples, we detected five differ-
ential peaks (see Figure 3A and Table 5). Of the five pep-
tides, two were also present in the list of differential peaks
comparing short PFS and long PFS (m/z = 2215.2849 and
2318.2202). The 5-peptide signature was used to retro-
spectively divide the total patient population in a PR vs.
no PR group (n = 27). In the patient group classified as no
PR, median PFS was significantly shorter at 125 days
(95% CI 115-135 days) vs. 231 days (95% CI 85-377
days) in the group classified as PR (p-value: 0.003).
Median overall survival of patients predicted to have no
PR was shorter, but not significantly, at 231 days (95% CI
41-421 days) vs. 478 days (95% CI 120-836 days) for
patients predicted to have a PR (p-value: 0.073) (Figure
3B).
Next we included also the Post-2 and EOT samples, result-
ing in five additional differential peptides (see Figure 3C
and Table 6). Again, there was no overlap between these
five peptides and the peptides found when using the pre-
treatment samples only. However, of these five peptides,
three peptides were also in the list of significant peptides
when comparing short PFS and long PFS over the three
time points (m/z = 1596.189, 1616.637 and 3215.194).
The 10-peptide signature was used to retrospectively
divide the total patient population in PR vs. no PR (n =
27). In the patient group classified as no PR, median PFS
was 125 days (95% CI 91-159 days) vs. 231 days (95% CI
117-345 days) in the group classified as PR (p-value
0.038). Median overall survival of patients predicted to
have no PR was shorter, but not significantly, at 231 days
(95% CI 36-426 days) vs. 613 days (95% CI 0-1253 days)
for patients predicted to have a PR (p-value: 0.077) (Fig-
ure 3D).
Classification analysis was performed using support vec-
tor machine with different combinations of features. The
LOOCV accuracy was again poor when using all 682 pep-
tides, at about 67%. When the five differential pre-treat-
ment peptides were used, the LOOCV accuracy was 89%
at 100% sensitivity and 83% specificity. The average accu-
racy over 10 runs was 74% using random feature selection
for five peptides. The LOOCV prediction accuracy was
reduced to 85%, at 100% sensitivity and 78% specificity,
when we used also the five peptides that changed differ-
ently in intensity level over the three time points (Figure 4
provides an overview of the study and study results).
Peptide pattern discriminating NSCLC patients from 
cancer-free controls
Finally, in an exploratory additional analysis, we com-
pared the serum peptide spectra of 13 cancer-free control
subjects (median age: 38 years old; range: 27-58 years old)
and the pre-treatment serum spectra of the 27 NSCLC
patients included in this study. We performed a principal
component analysis (PCA) analysis of the 40 profiles
using all 682 peptides, see Figure 5A. While there is over-
lap between the two groups in the three dimensional plot,
the healthy profiles (in red) are clustered at the bottom
right region. Furthermore, we observed no indication of
outliers in the dataset. Next we performed a supervised
Table 3: Comparison serum profiles short PFS vs. long PFS
m/z p-value
2489.3052 0.018082
2318.2202 0.030239
2209.0934 0.041789**
2215.2849 0.041789
2376.2096 0.041789
1545.616 0.048844
Six peaks were significantly differential comparing NSCLC patients 
with short progression-free survival and long progression-free 
survival. All peaks were up-regulated in the group with short 
progression-free survival. None of the six peaks were positively 
identified. Ordered by p-value. ** identified by Tempst et al. as high-
molecular-weight kininogen [19].Proteome Science 2009, 7:34 http://www.proteomesci.com/content/7/1/34
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analysis to identify peptides that were significantly differ-
ential in intensity between the two groups. For this pur-
pose, the Mann-Whitney U test was carried out on each of
the 682 peptides using all profiles. The peptides were
selected based on the criteria outlined in Methods, result-
ing in 47 peptides. A heat map of the intensities of the 47
peptides is shown in Figure 5B (see also Table 7). Figure
5C shows the spectra overlay of the top 8 most discrimi-
nating peaks, all of which have a p-value < 0.0001. Note
that for example the peak at m/z 1777.966 has a higher
intensity in NSCLC patients (blue) compared cancer-free
controls (red) and the peak at m/z 1039.6249 has a lower
intensity in NSCLC patients. We carried out classification
analysis using support vector machine. A grid search for
parameters was employed to find the best model accord-
ing to LOOCV. Using all 682 peptides, an LOOCV accu-
racy of 93% was achieved. When the 47 peptides selected
by the Mann-Whitney U test were used, the LOOCV accu-
racy was 98% with 100% sensitivity and 96% specificity.
To substantiate the result, we compared it to a random
selection of peptides. Using the same model selection
mechanism for support vector machine with 47 different
peptides randomly selected the average accuracy over 10
runs was 90%.
In this secondary analysis, control subjects were
unmatched for age and gender. We therefore also consid-
ered peptides that express differently in the two gender
Comparison serum profiles short PFS vs. long PFS Figure 2
Comparison serum profiles short PFS vs. long PFS. A, six peaks are differential between the two groups: short PFS 
(red) and long PFS (blue). Six randomly selected peaks. Each overlay contains spectra with normalized intensities. B, Kaplan-
Meier (1) time to progression and (2) overall survival curve in NSCLC patients, by prediction of short or long PFS using the 6-
peptide signature (intent-to-treat population, n = 27). C, median of the seven differential peaks comparing short PFS (red) and 
long PFS (blue) over the three time points: pre-treatment (PreTx), after two cycles of treatment (Post-2), and at end of treat-
ment (EOT) (Y-axis: intensity).D, Kaplan-Meier (1) time to progression and (2) overall survival curve in NSCLC patients, by 
prediction of short or long PFS using the 13-peptide signature (intent-to-treat population, n = 27).
 
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groups. For this comparison, four peptides were differen-
tial according to our criteria described above (m/z  =
1458.495, 3215.194, 2602.305, and 2789.091). Of these
four peptides, two are present in the list of 47 differential
peptides in the healthy versus NSCLC comparison. Ignor-
ing these two peptides, the signature composed of the
remaining 45 peptides yielded the same accuracy, sensitiv-
ity and specificity as that of the 47-peptide signature. Lit-
erature supports that serum peptidome patterns that
distinguished advanced cases of cancer from cancer-free
controls were unbiased by gender and age, except for the
fact that healthy subjects under 35 years could be distin-
guished with approximately 70% accuracy [19]. All partic-
ipating patients in our study were 35 years or older.
However, in the cancer-free control group, 4 individuals
were younger than 35 years and 9 individuals older than
35 years. Comparing these two groups, two peaks met the
criteria for differential (m/z = 1020.5133 and 855.0387).
These two peaks did not feature in the classifying signa-
ture between the NSCLC patients and the cancer-free con-
trols.
Peptide identification
For structural identification of signature peptides by MS/
MS, we performed an additional peptide capture on
another aliquot of the sera used for profiling. Sera with
highest intensity levels of signature ions were selected for
MS/MS. For each eluate, a series of four spots was applied
to a MALDI target plate, and candidate peaks were sub-
jected to MS/MS in the sample spot(s) associated with the
highest intensity for the pertinent peak. Seventeen pep-
tides were positively identified by MALDI-TOF/TOF-
based MS/MS analysis, see Table 8 as well as Tables 2, 4
and 6. See Figure 6 for an example of an annotated MS/MS
spectrum. In agreement with results by Villanueva et al. in
other tumor types, the serum peptide signatures mainly
consisted of small sets of overlapping sequences, trun-
cated in both ends in a ladder-like fashion. See Table 8 for
truncation ladder examples of Fibrinopeptide alpha,
Complement C3f, Complement C3 beta and Hemoglobin
alpha.
Discussion
In this study, we investigated the use of serum peptide
mass profiling by MALDI-TOF-MS coupled to bioinfor-
matics pattern discovery to predict treatment outcome of
advanced NSCLC patients treated with platinum-based
therapy. Additionally, peptide patterns found in NSCLC
patients were differential from those found in healthy vol-
unteers.
To our knowledge we are the first to report on a serum
peptide signature for response and survival prediction in
NSCLC patients treated with cisplatin-based chemother-
apy. For this study, serum samples were obtained not only
pre-treatment, but also during treatment and after com-
pletion of treatment, whereas serum proteomics studies
typically focus on pre-treatment samples only. In a study
by Taguchi et al., a predictive MALDI-TOF-MS-based pep-
tide algorithm for "good" or "poor" clinical outcome
upon epidermal growth factor tyrosine kinase inhibitor
(EGFR-TKI) therapy was established [20]. However, in
this study none of the peptides corresponding to the clas-
sifying m/z features were identified.
In our study, for the short PFS versus long PFS classifica-
tion, we achieved 82% accuracy with a 6-peptide-signa-
ture. A longer overall survival of the patients classified as
"long PFS" and a shorter overall survival of the patients
classified as "short PFS" was observed. Interestingly, per-
formance of the signature was improved upon inclusion
of 7 differential time-course peptides, the combined 13
peptide-ion signature achieving 86% accuracy. In this
regard, it has been previously reported that histological
response of locally advanced rectal cancer to radiochemo-
therapy could be predicted by SELDI-TOF-MS-based pro-
filing and comparison of serum samples collected pre-
treatment and during treatment [21].
For partial responders versus non-partial responders we
achieved 89% accuracy with a 5-peptide signature. Inclu-
sion of differential time-course peptides did not improve
performance of this signature. Longer duration of progres-
sion-free survival was strongly associated with tumour
response as seven out of eleven patients in our study with
long PFS also had a partial tumour response upon treat-
ment, compared to one out of eleven patients in the short
PFS group. This suggests that the survival signature is pre-
Table 4: Comparison time-course serum profiles short PFS vs. 
long PFS
m/z p-value peptide ID
3215.1939 0.0021001
1616.6366 0.010132 P-FPA
1292.4157 0.013272
1418.539 0.013272
1596.189 0.022018
1440.5407 0.043474
1670.5947 0.044759
Seven peaks were significantly differential comparing NSCLC patients 
with short progression-free survival and long progression-free 
survival, using three time points: pre-treatment, after two cycles of 
treatment and end of treatment. Ordered by p-value.
Abbreviation: P-FPA: phospho-fibrinopeptide A.Proteome Science 2009, 7:34 http://www.proteomesci.com/content/7/1/34
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dictive of therapy-outcome rather than prognostic. As the
Kaplan-Meier analysis showed, prediction of response
using the 5- or 10-peptide signatures was significantly
associated with a longer median PFS of those patients, but
this did not reach significance for overall survival.
In several MALDI serum peptide profiling studies involv-
ing other solid tumour types (bladder, breast, prostate,
thyroid) by Villanueva et al., methodologically compara-
ble to our study, the hypothesis was put forward that can-
cer-type specific changes in exopeptidase activities yield
surrogate biomarkers, reflected in the differential abun-
dance of cleavage products of common serum substrate
proteins [19,22]. The changes in exopeptidase activity
were superimposed on the proteolytic events of the com-
plement degradation and ex vivo coagulation pathways
and therefore serum-specific. Regulated peptides at m/z
1690.925, 1777.966 and 1865.002 correspond to those
identified in our study at 1690.90, 1777.94 and 1864.95,
respectively, previously identified by MALDI-TOF-TOF-
based MS/MS analysis as Complement C3f. The peptide at
2209.093 corresponds to the one we detected at 2209.08,
previously identified as HMW Kininogen [19].
We show that in NSCLC, the identified differential serum
peptides changing in abundance over time and those dis-
tinguishing NSCLC patients from cancer-free control sub-
jects consisted of truncated sequence clusters. The
Comparison serum profiles PR vs. no PR Figure 3
Comparison serum profiles PR vs. no PR. A, five differential peaks in the comparison between PR (red) versus PD+SD 
(blue) using pre-treatment samples. Five randomly selected in the same comparison. Each overlay contains spectra with nor-
malized intensities. B, Kaplan-Meier (1) time to progression and (2) overall survival curve in NSCLC patients, by prediction of 
PR or no PR, using the 5-peptide signature (intent-to-treat population, n = 27). C, median of the five differential peaks in the 
comparison between PR (red) versus PD+SD (blue) using three time points: pre-treatment (PreTx), after two cycles of treat-
ment (Post-2), and at end of treatment (EOT). D, Kaplan-Meier (1) time to progression and (2) overall survival curve in 
NSCLC patients, by prediction of PR or no PR, using the 10-peptide signature (intent-to-treat population, n = 27).
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Study flowchart Figure 4
Study flowchart. Serum profiling was performed in 27 NSCLC patients. "Feature list 1" represents total number of features 
before intensity and statistical filters. For each comparison, "Feature list 2" represents the number of differential peptide ions 
comparing pre-treatment sera (white filled circle), time-course sera (black filled circle) and pre-treatment plus time-course 
combined (grey filled circle). Accuracy (ac), sensitivity (sn) and specificity (sp) of algorithms are indicated. SVM: support vector 
machine; LOOCV: leave-one-out-cross validation; pts: patients.
Feature 
list 2
27 NSCLC patients
PFS Time-course Tumor response
PR SD/PD short Intermediate long
Feature list 1 
Intensity/
statistical filter
SVM/LOOCV 
Visual inspection
Feature 
list 2
682 Feature list 1 
Intensity/
statistical filter
SVM/LOOCV 
Visual inspection
Feature 
list 2
682 Feature list 1 
Intensity/
statistical filter
SVM/LOOCV 
Visual inspection
682
5 5
44
89% ac
100% sn
83% sp
85% ac
100% sn
78% sp
10
6 7
82% ac
82% sn
82% sp
13
86% ac
100% sn
73% sp
9 pts 18 pts 11 pts 11 pts 5 pts
excluded
Table 5: Comparison serum profiles PR vs. no PR
m/z p-value
2215.2849 0.0083178
2009.0039 0.015663
2318.2202 0.032445
2378.1982 0.042583
900.4258 0.048584
Five peaks were significantly differential comparing NSCLC patients 
with a partial response versus patients with stable or progressive 
disease. None of the 5 peptides were positively identified. Ordered by 
p-value.
Table 6: Comparison time-course serum profiles PR vs. no PR
m/z p-value peptide ID
1616.6366 0.007392 P-FPA
1596.189 0.011159
872.4325 0.018308
3215.1939 0.028873
1631.2111 0.040931
Five peaks were significantly differential comparing NSCLC patients 
with a partial response versus patients with stable or progressive 
disease, using three time points: pre-treatment, after two cycles of 
treatment and end of treatment. Ordered by p-value.
Abbreviation: P-FPA: phospho-fibrinopeptide AProteome Science 2009, 7:34 http://www.proteomesci.com/content/7/1/34
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identified peptides were derived from naturally occurring
serum peptides and protein precursors, and therefore not
likely to be tumor-derived, thus supporting the exopro-
tease hypothesis. For the predictive algorithms, it is
important to realize that these might be specific for the
treatment combination of bortezomib, cisplatin and gem-
citabine and may not apply to other treatment regimens.
For this exploratory analysis, we did not perform a power
calculation beforehand as we did not know the biological
variation in our patient groups, nor the number of peaks
we would measure as well as other variables. We only
knew the technical variation. It was therefore our
approach to collect as many samples as we could accom-
modate. It is crucial to validate and adjust the established
signatures with an independent cohort in a sufficiently
powered follow-up study. Additionally, since only one
report excludes an age and gender bias for a cancer-spe-
cific serum peptide signature, it is advisable to include
matched cancer-free control groups for the establishment
of cancer-specific peptide patterns.
Conclusion
Ideally, serum peptide mass profiling can be used to iden-
tify the therapeutic agents to which the tumour is sensi-
tive, enabling personalized medicine. The method
employed here requires readily accessible, non-invasively
obtainable patient samples, is high-throughput and cost-
efficient, all together important requirements for a screen-
ing platform as well as routine clinical use. The biggest
challenge might very well remain lack of reproducibility
related to sample collection in the clinic. In particular,
maintaining a constant and precise clotting time is often
Comparison serum profiles NSCLC vs. cancer-free controls Figure 5
Comparison serum profiles NSCLC vs. cancer-free controls. A, Principle Component Analysis (PCA) NSCLC vs. can-
cer-free control comparison. B, heat map of the 47 differential peaks. The peaks are ordered by median fold change between 
the two groups. C, spectra overlay of the 8 most differential peaks in the healthy (red) versus NSCLC (blue) comparison. Spec-
tra overlay of the 8 peaks randomly selected out of the remaining 635 peptides.
 
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difficult in clinical practice. Potentially, after initial dis-
covery of classifying algorithms, functional proteomics
tests will facilitate clinical implementation [23].
Methods
Patients and serum preparation
The training set included 27 patients with NSCLC who
were treated with chemotherapy and bortezomib as well
as 13 healthy volunteers [12]. All patients were treated
with cisplatin 70 mg/m2 day 1 and gemcitabine 1,000 mg/
Table 7: Comparison serum profiles NSCLC vs. cancer-free 
controls
m/z p-value peptide ID
1777.966 2.18E-06 C3f
1877.9926 9.96E-06
1545.616 2.49E-05
1690.9254 2.83E-05 C3f
1865.0022 2.83E-05 C3f
1039.6249 4.67E-05
1361.7417 5.97E-05
880.4127 7.62E-05
1041.6349 0.00010908
1955.9949 0.00013801
1015.6267 0.00017407
1087.5722 0.00017407
1063.6231 0.00034269
1092.5826 0.00034269
2318.2202 0.00034269
2536.2991 0.00034269
2105.4972 0.00047573
1396.5679 0.0005897
2112.022 0.00072868
987.5905 0.0013492
1616.6366 0.0016465 P-FPA
2324.1475 0.0018167 C3 beta
2104.998 0.0022066
2153.0655 0.0024291
1450.4893 0.0026719
2193.1036 0.0032253 C3 beta
898.4169 0.0035395
3427.8221 0.0035395
2163.9817 0.0046562
1670.5947 0.0050941
2099.1139 0.0072417
1456.5093 0.0078632
1418.539 0.0078923
1630.6679 0.0078923
2228.0362 0.0078923
2209.0934 0.0085948 **
3326.6863 0.0085948 Hb alpha
1434.5136 0.01017
3473.7545 0.01017 Hb alpha
1432.644 0.014108
1292.4157 0.01933
1440.5407 0.024299
2246.1744 0.030331
2789.0914 0.032609
3156.6207 0.035032 ITIH4
1276.456 0.037607
1458.4946 0.040342
47 peaks were significantly differential comparing NSCLC patients and 
healthy volunteers. Ordered by p-value. ** identified by Tempst et al. 
as high-molecular-weight kininogen [19]. Abbreviations: P-FPA: 
phospho-fibrinopetide A; C3 beta/f: complement C3 beta/f; Hb alpha: 
hemoglobin alpha; seAlb: serum albumen; ITIH4: inter-alpha-trypsin 
inhibitor heavy chain H4
Table 7: Comparison serum profiles NSCLC vs. cancer-free 
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m2 days 1 and 8, every 21 days for up to 6 cycles. Fifteen
patients were treated with bortezomib on days 1 and 8 of
every cycle (ten patients at 1.0 mg/m2 and five patients at
1.3 mg/m2). Twelve patients were treated with borte-
zomib on days 1,4,8 and 11 of every cycle (one patient at
0.7 mg/m2 and eleven patients at 1.0 mg/m2). There was
no indication of superior clinical activity of any schedule
of bortezomib in combination with cisplatin and gemcit-
abine [12]. Blood samples were obtained in BD Vacu-
tainer glass "red-top" tubes (Becton Dickinson, Franklin
Lakes, NJ), allowed to clot for 1 hour, and then centri-
fuged at 1500 g for 10 minutes. Sera were stored in poly-
propylene cryovials (Nunc; Roskilde, Denmark) at -80°C.
Studies were performed after obtaining patient consent
and under protocols approved by the institutional review
board.
Serum sample processing and mass spectrometry
Samples were processed in randomized order, along with
control samples to check consistency in each experiment.
Magnetic Dynabeads® RPC 18 (Invitrogen, San Diego, CA)
were used for serum peptide capture using the
KingFischer96 platform, as described previously [11].
Briefly, in a 96-well format, magnetic beads were washed
and equilibrated twice in 200 μl 200 mM NaCl/0.1% TFA,
transferred to a mix of 20 μl serum sample and 2 volumes
of 0.2% n-octyl glucoside/0.5% TFA (premixed for 5
min), incubated for 2 min, washed thrice with 0.1% TFA,
and eluted for 2 min with 40 μl 50% acetonitrile.
Processed samples (1.5 μl eluate) were mixed with 2 vol-
umes α-cyano-4-hydroxycinnamic acid matrix (6.2 mg/
ml in 56% acetonitrile, 36% methanol; Agilent, Santa
Clara, CA) and 0.7 μl of this mix was spotted on a MALDI
plate. A 4800 MALDI-TOF/TOF mass spectrometer
(Applied Biosystems, Foster City, CA) was used to record
with 5000 shots per spectrum (reflectron mode) serum
peptide profiles in the mass range of m/z 800-4000 [11].
Internal calibration was used using a list of exact masses
for fibrinogen α/fibrinopeptide A peptides as major com-
ponents of serum samples. For MS/MS analysis, stepwise
attempts of 5000 shots at a time generated spectra for
identification by the Mascot search engine or manual
identification. For Mascot searches, the SwissProt data-
base (release 54.7) was used at a mass window of 10 ppm
for MS and a 1-Da tolerance for MS/MS. Final scores were
Tandem MS-based peptide identification Figure 6
Tandem MS-based peptide identification. As an example of tandem-MS generated spectra, the annotated MS/MS spec-
trum of precursor mass 1545.58 is displayed.Proteome Science 2009, 7:34 http://www.proteomesci.com/content/7/1/34
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obtained by narrowing down the window. For manual
identification, spectra were compared with theoretical
peptide fragments of reported candidate proteins [19].
Fragments having a predicted mass differing less than 10
ppm from the mass of any of the 87 significantly regulated
peaks from our profiling study were identified using Find-
Pept http://www.expasy.ch[19]. Fragmentation patterns
were predicted using MS-Product http://prospec
tor.ucsf.edu/prospector/mshome.htm, requiring that at
least 3 prominent peaks in the experimental spectrum
should match b or y ions from the theoretical table.
Signal processing
Spectra were pre-processed using MarkerView, version 1.2
(Applied Biosystems) with a mass tolerance of 200.0 ppm
and minimum intensity at 100.0 units. Total signal inten-
sity of all peptide peaks was used for normalization.
Statistical analysis
Feature selection was performed using the Mann-Whitney
U test on each peptide detected in the pre-processing step.
We used a common threshold of 5% for the p-value. As p-
values were not adjusted for multiple testing, we took
additional measures to guard from false discovery. To
reduce differences due to noise, each peptide was sub-
jected to intensity filtering, requiring that the median
intensity of at least one group must be greater than 80
units and the fold change of the median intensities of the
two groups must be greater than 1.5. For time course anal-
ysis of the three time points, we treated the problem as
three binary comparisons. For each comparison, a paired,
two-sided signed rank test was carried out. Each peptide
was again subjected to intensity filtering. The results of the
three comparisons were merged where the significance
level of each peptide was the minimum of the three p-val-
ues. Similarly, we analyzed dynamic peptide profiles
(time-course), using the group information, in order to
identify peptides of which the intensity level changes dif-
ferently between different clinical groups. Finally, support
vector machine with the Gaussian kernel was used to con-
struct classification models. A two dimensional grid
search was carried out to set model parameters using the
leave-one-out cross-validation (LOOCV) measure. Analo-
gously to Villanueva et al. [19], we used a statistical test for
feature selection. This procedure is based on class label,
thus bias might be introduced. Nevertheless, this strategy
was shown to be effective in previous studies [19,22].
Median duration of progression-free and overall survival
was calculated using the Kaplan-Meier method; p-values
according to the log-rank test (SPSS Statistics17.0, SPSS
Inc., Chicago, IL).
List of abbreviations
CI: confidence interval; EOT: end of treatment; LOOCV:
leave-one-out cross-validation; MALDI-TOF MS: matrix-
assisted laser desorption/ionization time-of-flight mass
spectrometry; MS: mass spectrometry; NSCLC: non-small
cell lung cancer; OS: overall survival; PCA: principal com-
Table 8: MS/MS identification results
Peptide ID m/z Peptide residue location Peptide amino acid sequence Signature(s)
BK 904.4676 381-388 RPPGFSPF Time course (44)
P-FPA 1616,6366 20-35 ADS*GEGDFLAEGGGVR Time course (44); PFS (13);
Response (10);
NSCLC vs. Healthy (47)
FPA 1536,6906 20-35 ADSGEGDFLAEGGGVR Time course (44)
FPA 1350,6275 22-35 SGEGDFLAEGGGVR Time course (44)
FPA 1263,5958 23-35 GEGDFLAEGGGVR Time course (44)
Glu-FPB 1552.669 31-44 EGVNDNEEGFFSA Time course (44)
FPB 1129.4849 34-43 NDNEEGFFSAR Time course (44)
C3f 1865,0022 1304-1319 SSKITHRIHWESASLL Time course (44)
C3f 1777,966 1305-1319 SKITHRIHWESASLL Time course (44)
C3f 1690,9254 1306-1319 KITHRIHWESASLL Time course (44)
C3 beta 2324,1475 23-42 SPMYSIITPNILRLESEETM NSCLC vs. Healthy (47)
C3 beta 2193,1036 23-41 SPMYSIITPNILRLESEET NSCLC vs. Healthy (47)
Hbα 3473,7545 2-34 VLSPADKTNVKAAWGKVGAHAGEYGAEALERMF NSCLC vs. Healthy (47)
Hbα 3326,6863 2-33 VLSPADKTNVKAAWGKVGAHAGEYGAEALERM NSCLC vs. Healthy (47)
seAlb 2567,3659 27-48 HKSEVAHRFKDLGEENFKALVL Time course (44)
ITIH4 3156,6207 617-644 NVHSGSTFFKYYLQGAKIPKPEASFSPR Time course (44);
NSCLC vs. Healthy (47)
CFXIII A 2602,3048 43-67 AVPPNNSNAAEDDLPTVELQGVVPR Time course (44)
Peptides were identified from the 44-peptide ion time course signature ("time course (44)"), the 13-peptide ion "long PFS" vs. "short PFS" signature 
("PFS (13)"), the 10-peptide ion "PR" vs. "no PR" signature ("Response (10)") and the 47-peptide ion NSCLC vs. Healthy comparison ("NSCLC vs. 
Healthy (47)"). Abbreviations: FPA: fibrinopeptide A; P-FPA: phospho-fibrinopeptide A (phosphorylation site indicated by *); FBP: fibrinopeptide B; 
Glu-FBP: Glu-1-Fibrinopeptide B; C3f: complement C3f; C3b: complement C3beta; Hb alpha: hemoglobin alpha; seAlb: serum albumen; ITIH4: inter-
alpha-trypsin inhibitor heavy chain H4; CFXIIIA: coagulation factor XIIIA.Publish with BioMed Central    and   every 
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ponent analysis; PD: progressive disease; PFS: progres-
sion-free survival; PR: partial response; PreTx: pre-
treatment; RECIST: Response Evaluation Criteria in Solid
Tumors; SD: stable disease; SELDI: surface-enhanced laser
desorption/ionization.
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